CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10016 |
|---|---|
| Brand Name | Velcade |
| Generic Name | Bortezomib |
| Strength | 3.5mg/vial |
| Tumour Type | Myeloma |
| Indication | Multiple Myeloma |
| Funding Request | For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | N/A |
| Manufacturer | Janssen |
| Sponsor | Cancer Care Ontario Hematology Disease Site Group |
| Submission Date | October 29, 2012 |
| Submission Deemed Complete | November 5, 2012 |
| Submission Type | New Indication |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | November 13, 2012 |
| Check-point meeting | December 18, 2012 |
| pERC Meeting | February 21, 2013 |
| Initial Recommendation Issued | March 7, 2013 |
| Feedback Deadline ‡ | March 21, 2013 |
| Final Recommendation Issued | March 25, 2013 |
| Notification to Implement Issued | April 11, 2013 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
